3M Drug Delivery Systems Corporate Profile
For over 50 years, pharmaceutical companies have looked to 3M Drug Delivery Systems for ingenious inhalation and transdermal systems, components and manufacturing to help enable success.
For over 50 years, pharmaceutical companies have looked to 3M Drug Delivery Systems for ingenious inhalation and transdermal systems, components and manufacturing to help enable success. With proven international accomplishments in technology, development, manufacturing and regulatory, partnering with 3M helps ensure a smooth process critical to speed to market.
Systems: 3M can fulfill your inhalation needs with both Metered Dose Inhaler and Dry Powder Inhaler systems. Our transdermal offerings include microneedle and passive drug-in-adhesive technologies.
Components: 3M offers a wide variety of transdermal backings, membranes, liners and tapes, as well as the FDA-approved 3M Integrated Dose by Dose Counter, in conjunction with an MDI product and the most complete line of compatible inhalation valves, canisters and actuators.
Contract Manufacturing: Our cGMP compliant facilities can reliably meet your inhalation, transdermal, transmucosal, oral or topical needs from clinical to commercial supply.
We understand partners may be looking for ways to improve drug performance and patient compliance. As we develop new products with our partners, we leverage company-wide resources and more than 100 years of time-tested 3M technologies, including films, adhesives, hardware design, coatings and manufacturing. In addition, we can assess potential partners’ needs to determine whether our technology is a fit with a complimentary feasibility study.
Let us prove why 3M technology is relied upon by 50% of all MDIs worldwide and 80% of all transdermal systems in the U.S. Visit www.3m.com/dds to learn more.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Adding SYLOID® Mesoporous Silica to Improve Run Time and Yield for Micronization Processes
May 9th 2025A must-read for anyone in the industry looking to enhance their micronization processes. Discover how adding low percentages of SYLOID® mesoporous silica can significantly improve the run time and yield of jet milling processes for hard-to-process Active Pharmaceutical Ingredients (APIs). Imagine achieving a more consistent feed rate and a homogenous final product simply by pre-blending SYLOID® mesoporous silica with your APIs. Grace & Microsize conducted experiments that reveal substantial improvements in both run time and yield, making this paper an essential guide for professionals aiming to optimize their manufacturing processes and boost efficiency and feed rate consistency.
